Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes.
Age-related macular degeneration
Macular atrophy
Macular incidence
Macular progression
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
23
10
2022
accepted:
07
07
2023
revised:
28
06
2023
medline:
27
11
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
Τo evaluate the evolution of macular atrophy (MA) in patients with neovascular AMD (nAMD), compared with their fellow eyes exhibiting dry AMD (dAMD). This retrospective study included 124 patients from three centers treated with anti-VEGF in their nAMD eye and having dAMD in the fellow eye. Patients without MA at baseline were analyzed to study the time to first MA development. Synchronous and unsynchronous time course of MA was also studied. MA was evaluated using near-infrared images, while all available optical coherence tomography (OCT) images were used to confirm the criteria proposed by the Classification of Atrophy Meetings group for complete MA. MA first detection in nAMD eyes increased significantly from year 2 to 6 compared to dAMD eyes. Over the study's follow-up, 45.1% of nAMD-E developed MA, compared to 16.5% of fellow eyes (p < 0.001). When MA in the two eyes was compared in a synchronous paired manner over 4 years, nAMD eyes had an average MA progression rate of 0.275 mm/year versus 0.110 mm/year in their fellow dAMD eyes. Multivariate ANOVA revealed significant time (p < 0.001), eye (p = 0.003), and time-eye interaction (p < 0.001) effects. However, when MA did develop in dAMD eyes and was compared in an asynchronous manner to MA of nAMD eyes, it was found to progress faster in dAMD eyes (dAMD: 0.295 mm/year vs. nAMD: 0.176 mm/year) with a significant time-eye interaction (p = 0.015). In this study, a significant difference in MA incidence and progression was documented in eyes with nAMD under treatment, compared to fellow eye exhibiting dAMD. Eyes with nAMD tended to develop more MA compared to fellow dAMD eyes. However, when atrophy did develop in the fellow dAMD eyes, it progressed faster over time compared to MA in nAMD eyes.
Identifiants
pubmed: 37566302
doi: 10.1007/s00417-023-06168-0
pii: 10.1007/s00417-023-06168-0
pmc: PMC10667153
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3425-3436Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Ophthalmology. 2016 Jun;123(6):1269-77
pubmed: 26996339
Ophthalmology. 1991 Jul;98(7):1128-34
pubmed: 1843453
Retina. 2010 Oct;30(9):1333-49
pubmed: 20924258
Ophthalmol Retina. 2017 Jan-Feb;1(1):34-41
pubmed: 28630947
Ophthalmology. 2017 Jan;124(1):97-104
pubmed: 28079023
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Curr Eye Res. 2021 Jul;46(7):988-994
pubmed: 33174459
Ophthalmol Retina. 2017 Jul - Aug;1(4):304-313
pubmed: 31047516
Bull World Health Organ. 2004 Nov;82(11):844-51
pubmed: 15640920
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Am J Ophthalmol. 2020 Apr;212:169-174
pubmed: 31945331
Ophthalmology. 2018 Mar;125(3):369-390
pubmed: 29110945
Ophthalmol Retina. 2022 Oct;6(10):914-921
pubmed: 35460930
Ophthalmology. 2018 Dec;125(12):1913-1928
pubmed: 30060980
Retina. 2016 Oct;36(10):1843-50
pubmed: 27135213
Ophthalmology. 2020 Jun;127(6):769-783
pubmed: 32081489
Ophthalmol Retina. 2020 Sep;4(9):889-898
pubmed: 32418846
Retina. 2015 Feb;35(2):176-86
pubmed: 25387047
Ophthalmology. 2020 Feb;127(2):198-210
pubmed: 31619357
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Retina. 2020 Feb;40(2):266-272
pubmed: 31972796
Ophthalmology. 2020 Apr;127(4):523-532
pubmed: 31718842
Ophthalmology. 2011 Sep;118(9):1844-51
pubmed: 21496928
Transl Vis Sci Technol. 2018 Dec 28;7(6):40
pubmed: 30619660
JAMA Ophthalmol. 2013 Jan;131(1):110-1
pubmed: 23307222
Acta Ophthalmol. 2012 Jun;90(4):e281-7
pubmed: 22269083
Lancet. 2013 Oct 12;382(9900):1258-67
pubmed: 23870813
Ophthalmology. 2013 Nov;120(11):2292-9
pubmed: 23642856
Acta Ophthalmol. 2016 Dec;94(8):e757-e764
pubmed: 27417506
Ophthalmology. 2020 Jun;127(6):784-792
pubmed: 31899035
Ophthalmology. 2014 Jan;121(1):150-161
pubmed: 24084496
Ophthalmology. 2019 Jan;126(1):75-86
pubmed: 30301555
Retina. 2015 May;35(5):966-74
pubmed: 25627089
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):209-14
pubmed: 20737163
Ophthalmology. 2020 Oct;127(10):1360-1370
pubmed: 32402555
Jpn J Ophthalmol. 2020 Jul;64(4):338-345
pubmed: 32447586
Eye (Lond). 2017 Jul;31(7):1042-1050
pubmed: 28282062